10 Best Penny Stocks to Buy Now - 1 of 10

 
 

bluebird bio (NASDAQ:BLUE)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
4 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$5.74 (489.4% Upside)

About bluebird bio

bluebird bio logobluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
3/27/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$6.00
3/27/2024Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00
3/19/2024WedbushLower Price TargetNeutral ➝ Neutral$1.72 ➝ $1.68
3/5/2024HSBCLower Price TargetReduce ➝ Reduce$2.31 ➝ $1.02
1/9/2024William BlairReiterated RatingMarket Perform
1/8/2024WedbushReiterated RatingNeutral$3.00
12/21/2023Bank of AmericaLower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
12/15/2023Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
12/12/2023Robert W. BairdLower Price TargetOutperform ➝ Outperform$10.00 ➝ $7.00
12/11/2023HSBCDowngradeHold ➝ Reduce
 

Biden replacement revealed? (Ad)

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report